Michael Cola served as the CEO of Avalo Therapeutics from February 2020 until February 2022. He brought with him over two decades of experience in the pharmaceutical sector. His tenure began shortly after Avalo merged with Aevi, where he was...

Michael Cola served as the CEO of Avalo Therapeutics from February 2020 until February 2022. He brought with him over two decades of experience in the pharmaceutical sector. His tenure began shortly after Avalo merged with Aevi, where he was also the CEO. During his leadership, he was involved in the development and strategic direction of the company, focusing on treatments for serious diseases. He had a notable compensation structure that included a reduced base salary with the promise of stock options, reflecting a commitment to align his interests with the company's performance. In 2021, his total compensation was around $2.7 million, which included a significant bonus based on performance metrics set by the company's board. Cola’s previous roles include significant positions at Shire Pharmaceutical and Safeguard Scientifics, giving him a strong background in business development and product commercialization. He holds degrees in biology and physics, as well as a master’s in biomedical science, all of which support his technical and strategic insight into the pharmaceutical industry.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Avalo Therapeutics CEOs

A

Michael Cola

Ex-CEO of Avalo Therapeutics

Sector of Economy

Healthcare

CEO of Avalo Therapeutics for

2 years 0 months (Feb 2020 - Feb 2022)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Michael Cola

Holdings

See how much did Michael Cola make over time.

Michael Cola held significant stock options during his time as CEO, which were set to vest over four years. His compensation included a reduced cash salary paired with stock-based incentives tied to company performance, showcasing a strategic approach towards executive...

Michael Cola held significant stock options during his time as CEO, which were set to vest over four years. His compensation included a reduced cash salary paired with stock-based incentives tied to company performance, showcasing a strategic approach towards executive compensation. His total compensation saw fluctuations notably in 2021 with a total exceeding $2.6 million, a reflection of his performance-driven role at Avalo. Given the termination of his employment in February 2022, he was eligible for continued payments and benefits including fully vested options that could be exercised until early 2023. At the height of his role, the strength of his stock options and performance bonuses underscored both his leadership and the growth dynamics of the company during that period. As of now, his equity stake has changed dramatically from his initial holdings, highlighting the volatility typical in biotech firms, especially for transitioning leadership.

No data yet.

Insider Trading

See recent insider trades of Michael Cola.

No insider trades found for this CEO.

Compensation History

See how much did Michael Cola make over time.

Michael Cola's compensation during his tenure at Avalo Therapeutics was structured to align his interests with the company’s performance. In 2021, his total compensation was about $2.7 million, which included a base salary that had been significantly reduced to $35,568, reflecting a choice to have more incentives tied to the company's success. The bulk of his compensation came from performance bonuses and vested stock options, a move that linked his pay directly to Avalo's achievements in the market. This strategy intended to motivate Cola to drive the company forward and achieve its corporate goals. His compensation strategy highlighted a thought process often used in the biotech industry, where leaders are incentivized to focus on long-term growth rather than short-term gains. Cola's compensation saw changes alongside the company's performance metrics set forth by the board, indicating an approach that values executive accountability.

Year

2022

Total Compensation

$945.42K

Salary

$62.50K

Board Justification

The compensation philosophy aims to align executive compensation with company performance, peer benchmarking, and retention strategies, ensuring that compensation reflects individual and company performance metrics.

Bonus

$17.26K

Board Justification

Annual bonus earned based on the achievement of the Company’s goals, prorated to reflect the days worked in 2022, payable when such annual bonuses are paid to the Company’s existing personnel.

Other

$865.66K

Board Justification

Severance earned, including continued payment of base salary for 18 consecutive months, unused accrued vacation, and COBRA paid to Mr. Cola pursuant to his separation agreement.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock grants vested in 2022 as Mr. Cola's employment ended on February 14, 2022.

Performance Metrics

The performance metrics for determining the compensation include the achievement of the Company’s goals as recommended by the Compensation Committee.

Other Avalo Therapeutics CEOs

Here are other CEOs of Avalo Therapeutics

Garry A. Neil

CEO of Avalo Therapeutics

February 2022 - Present